Application of quinazoline alkaloid HJ-70 in preparation of anti-epilepsy drugs
By developing the quinazoline alkaloid compound HJ-70 for the preparation of antiepileptic drugs, the problems of insufficient efficacy and side effects of existing drugs for some patients have been solved, and the antiepileptic efficacy and safety in mouse models have been improved.
Patent Information
- Application Number
- CN202610842882.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-06-11
- Publication Date
- 2026-07-17
AI Technical Summary
Existing antiepileptic drugs are effective for about one-third of patients, but are often accompanied by side effects such as sedation, ataxia, cognitive impairment, liver and kidney toxicity, and cardiovascular risks. There is a lack of drug candidates with novel structures, unique mechanisms of action, and good safety profiles.
HJ-70, a quinazoline alkaloid compound, is used to develop drugs for the treatment or prevention of epilepsy and related diseases, including epilepsy, convulsions, and epileptiform seizures. These drugs can be used alone or in combination with existing antiepileptic drugs through various routes of administration and dosage forms.
HJ-70 showed significant antiepileptic activity in mouse models, reducing seizure frequency, mitigating seizure severity, and improving seizure protection rate, providing a novel and safe antiepileptic drug option.
Smart Images
Figure CN122398808A_ABST
Abstract
Citation Information
Patent Citations
A novel class of KCNQ potassium channel agonists, their preparation method and uses
CN103073455B
Isoquinoline alkaloid compound and preparation method and application thereof
CN115477650B